Benitec Biopharma Ltd Stock Today
| BNTC Stock | USD 16.79 1.13 7.22% |
PerformanceGood
| Odds Of DistressBelow Average
|
Benitec Biopharma is trading at 16.79 as of the 21st of March 2025, a 7.22% increase since the beginning of the trading day. The stock's open price was 15.66. Benitec Biopharma has about a 33 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 19.82 M outstanding shares of which 148.67 K shares are currently shorted by private and institutional investors with about 1.35 trading days to cover. More on Benitec Biopharma Ltd
Moving against Benitec Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Benitec Stock Highlights
Benitec Biopharma Ltd (BNTC) is traded on NASDAQ Exchange in USA. It is located in 3940 Trust Way, Hayward, CA, United States, 94545 and employs 16 people. Benitec Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 215.39 M. Benitec Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.82 M outstanding shares of which 148.67 K shares are currently shorted by private and institutional investors with about 1.35 trading days to cover.
Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check Benitec Biopharma Probability Of Bankruptcy
Ownership AllocationBenitec Biopharma holds a total of 19.82 Million outstanding shares. 30% of Benitec Biopharma Ltd outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Benitec Ownership Details
Benitec Biopharma Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Benitec Biopharma market risk premium is the additional return an investor will receive from holding Benitec Biopharma long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1503 | |||
| Jensen Alpha | 0.743 | |||
| Total Risk Alpha | 1.08 | |||
| Sortino Ratio | 0.1888 |
Benitec Stock Against Markets
Benitec Biopharma Corporate Management
| Michael Graham | Founding Scientist and Head of Discovery | Profile | |
| Bryan Dulhunty | Chief Officer | Profile | |
| Sophie Mukadam | Chief Officer | Profile | |
| Claudia Kloth | Senior Manufacturing | Profile | |
| Craig Lewis | Chief Adviser | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.